These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
654 related articles for article (PubMed ID: 10189543)
1. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. The Diabetes Prevention Program Research Group Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543 [TBL] [Abstract][Full Text] [Related]
2. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. Flórez H Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072 [TBL] [Abstract][Full Text] [Related]
3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231 [TBL] [Abstract][Full Text] [Related]
4. [Progress in the prevention of type 2 diabetes]. Schernthaner G Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944 [TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525 [TBL] [Abstract][Full Text] [Related]
7. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Azen SP; Peters RK; Berkowitz K; Kjos S; Xiang A; Buchanan TA Control Clin Trials; 1998 Apr; 19(2):217-31. PubMed ID: 9551285 [TBL] [Abstract][Full Text] [Related]
8. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Buchanan TA; Xiang AH; Peters RK; Kjos SL; Marroquin A; Goico J; Ochoa C; Tan S; Berkowitz K; Hodis HN; Azen SP Diabetes; 2002 Sep; 51(9):2796-803. PubMed ID: 12196473 [TBL] [Abstract][Full Text] [Related]
9. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563 [TBL] [Abstract][Full Text] [Related]
10. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Knowler WC; Hamman RF; Edelstein SL; Barrett-Connor E; Ehrmann DA; Walker EA; Fowler SE; Nathan DM; Kahn SE; Diabetes; 2005 Apr; 54(4):1150-6. PubMed ID: 15793255 [TBL] [Abstract][Full Text] [Related]
11. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. Schuster D; Gaillard T; Rhinesmith S; Habash D; Osei K Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629 [TBL] [Abstract][Full Text] [Related]
12. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
13. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Hershon KS; Hershon PM Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922 [TBL] [Abstract][Full Text] [Related]
14. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Kumar S; Prange A; Schulze J; Lettis S; Barnett AH Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807 [TBL] [Abstract][Full Text] [Related]
15. Effects of troglitazone on insulin sensitivity. Henry RR Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499 [TBL] [Abstract][Full Text] [Related]
16. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL; Faulds D Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691 [TBL] [Abstract][Full Text] [Related]
17. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin. Blonde L; Sandberg MI; Guthrie RD Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262 [No Abstract] [Full Text] [Related]
18. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421 [TBL] [Abstract][Full Text] [Related]